These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26142890)

  • 1. Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis.
    Fu H; Cao D; Boye KS; Curtis B; Schuster DL; Kendall DM; Ascher-Svanum H
    Diabetes Ther; 2015 Sep; 6(3):317-28. PubMed ID: 26142890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
    Grimm M; Li Y; Brunell SC; Blase E
    Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.
    Yin TT; Bi Y; Li P; Shen SM; Xiong XL; Gao LJ; Jiang C; Wang Y; Feng WH; Zhu DL
    Diabetes Ther; 2018 Jun; 9(3):1253-1267. PubMed ID: 29744819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response.
    Gu T; Hong T; Zhang P; Tang S; Bi Y; Lu H; Men L; Ma D; Zhu D
    Diabetes Ther; 2018 Apr; 9(2):771-787. PubMed ID: 29524190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial.
    Rojas A; Sposetti G; Gross JL; Barbieri DE; Duan R; Linetzky B; De Lana JM; Stempa O; Rodriguez A
    Diabetol Metab Syndr; 2016; 8():69. PubMed ID: 27660663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
    Yu M; Yuan GY; Zhang B; Wu HY; Lv XF
    Diabetes Ther; 2020 May; 11(5):1147-1159. PubMed ID: 32277401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial.
    Yang W; Yang Z; Zhao J; Lu H; Luo T
    Trials; 2016 Sep; 17(1):470. PubMed ID: 27669747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis.
    Ascher-Svanum H; Zagar A; Jiang D; Schuster D; Schmitt H; Dennehy EB; Kendall DM; Raskin J; Heine RJ
    Diabetes Ther; 2015 Sep; 6(3):303-16. PubMed ID: 26159935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y; Li L; De Peng Y; Song GY; Ye SD; Du LY; Hou JN; Ji QH
    Diabetes Ther; 2019 Aug; 10(4):1435-1452. PubMed ID: 31228090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis.
    Fu H; Cao D; Boye KS; Curtis B; Schuster DL; Kendall DM; Ascher-Svanum H
    Diabetes Ther; 2015 Dec; 6(4):651. PubMed ID: 26438106
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized Diabetes Management: Moving from Algorithmic to Individualized Therapy.
    Subramanian S; Hirsch IB
    Diabetes Spectr; 2014 May; 27(2):87-91. PubMed ID: 26246764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.
    Lankisch MR; Del Prato S; Dain MP; Mullins P; Owens DR
    Prim Care Diabetes; 2016 Feb; 10(1):51-9. PubMed ID: 26150328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine.
    Ioacara S; Guja C; Reghina A; Martin S; Sirbu A; Fica S
    J Diabetes Res; 2015; 2015():962346. PubMed ID: 26176017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A second-generation inhaled insulin for diabetes mellitus.
    Ledet G; Graves RA; Bostanian LA; Mandal TK
    Am J Health Syst Pharm; 2015 Jul; 72(14):1181-7. PubMed ID: 26150567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Insulin Glargine on Recovery of Patients with Diabetic Ketoacidosis: A Randomized Controlled Trial.
    Houshyar J; Bahrami A; Aliasgarzadeh A
    J Clin Diagn Res; 2015 May; 9(5):OC01-5. PubMed ID: 26155506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.